CD19: a biomarker for B cell development, lymphoma diagnosis and therapy
- PMID: 23210908
- PMCID: PMC3520838
- DOI: 10.1186/2162-3619-1-36
CD19: a biomarker for B cell development, lymphoma diagnosis and therapy
Abstract
The human CD19 antigen is a 95 kd transmembrane glycoprotein belonging to the immunoglobulin superfamily. CD19 is classified as a type I transmembrane protein, with a single transmembrane domain, a cytoplasmic C-terminus, and extracellular N-terminus. CD19 is a biomarker for normal and neoplastic B cells, as well as follicular dendritic cells. CD19 is critically involved in establishing intrinsic B cell signaling thresholds through modulating both B cell receptor-dependent and independent signaling. CD19 functions as the dominant signaling component of a multimolecular complex on the surface of mature B cells, alongside complement receptor CD21, and the tetraspanin membrane protein CD81 (TAPA-1), as well as CD225. Through study of CD19 transgenic and knockout mouse models, it becomes clear that CD19 plays a critical role in maintaining the balance between humoral, antigen-induced response and tolerance induction. This review also summarized latest clinical development of CD19 antibodies, anti-B4-bR (an immunotoxin conjugate), blinatumomab (BiTE), and SAR3419 (huB4-DM4), a novel antibody-drug conjugate.
Figures
Similar articles
-
_targeting CD19 in B-cell lymphoma: emerging role of SAR3419.Cancer Manag Res. 2013 Aug 27;5:225-33. doi: 10.2147/CMAR.S45957. eCollection 2013. Cancer Manag Res. 2013. PMID: 24023523 Free PMC article. Review.
-
Design of Coltuximab Ravtansine, a CD19-_targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.Mol Pharm. 2015 Jun 1;12(6):1703-16. doi: 10.1021/acs.molpharmaceut.5b00175. Epub 2015 Apr 27. Mol Pharm. 2015. PMID: 25856201
-
Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes.J Exp Med. 1993 Oct 1;178(4):1407-17. doi: 10.1084/jem.178.4.1407. J Exp Med. 1993. PMID: 7690834 Free PMC article.
-
The novel CD19-_targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models.Haematologica. 2019 Aug;104(8):1633-1639. doi: 10.3324/haematol.2018.211011. Epub 2019 Feb 7. Haematologica. 2019. PMID: 30733273 Free PMC article.
-
SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.Clin Cancer Res. 2011 Oct 15;17(20):6448-58. doi: 10.1158/1078-0432.CCR-11-0485. Clin Cancer Res. 2011. PMID: 22003072 Review.
Cited by
-
Adaptable antibody Nanoworms designed for non-Hodgkin lymphoma.Biomaterials. 2020 Dec;262:120338. doi: 10.1016/j.biomaterials.2020.120338. Epub 2020 Aug 31. Biomaterials. 2020. PMID: 32916604 Free PMC article.
-
Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.Onco_target. 2017 Jan 24;8(4):7201-7207. doi: 10.18632/onco_target.12786. Onco_target. 2017. PMID: 27776353 Free PMC article. Review.
-
Anti-CD20 Agents for Multiple Sclerosis: Spotlight on Ocrelizumab and Ofatumumab.Brain Sci. 2020 Oct 20;10(10):758. doi: 10.3390/brainsci10100758. Brain Sci. 2020. PMID: 33092190 Free PMC article. Review.
-
CAR-T Cell Therapy: the Efficacy and Toxicity Balance.Curr Hematol Malig Rep. 2023 Apr;18(2):9-18. doi: 10.1007/s11899-023-00687-7. Epub 2023 Feb 10. Curr Hematol Malig Rep. 2023. PMID: 36763238 Free PMC article. Review.
-
Single-cell multi-omic topic embedding reveals cell-type-specific and COVID-19 severity-related immune signatures.bioRxiv [Preprint]. 2023 Jun 1:2023.01.31.526312. doi: 10.1101/2023.01.31.526312. bioRxiv. 2023. Update in: Cell Rep Methods. 2023 Aug 18;3(8):100563. doi: 10.1016/j.crmeth.2023.100563 PMID: 36778483 Free PMC article. Updated. Preprint.
References
-
- Carter RH, Barrington RA. Signaling by the CD19/CD21 complex on B cells. Curr Dir Autoimmun. 2004;7:4–32. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials